Ever since the success of producing inhalable insulin, drug delivery via
pulmonary administration has been an intriguing way to treat chronic disorders.
Pulmonary delivery system for nanotechnology is a relatively recent approach,
especially when related to lung cancer therapy. The therapeutic ratio is increased by
inhalation delivery, which delivers a high dose of the drug directly to the lungs without
damaging other body organs. Despite extensive studies into targeted delivery and
specific molecular inhibitors (gene delivery), cytotoxic drug delivery via inhalation is
still considered a critical component of lung cancer treatment. Nanotechnology-based
inhalation chemotherapy has been proven to be practical and more successful than
conventional chemotherapy, with fewer adverse effects. Many nanocarriers have
recently been studied for inhalation treatments of lung cancer, including liposomes,
polymeric micelles, polymeric NPs, solid lipid NPs, and inorganic NPs. The potential
for NPs-based local lung cancer targeting via inhalation, as well as the challenges that
come with it, are explored here.
Keywords: Inhalable Approach, Lung Cancer, Nano Formulation.
